Raiffeisen Bank International AG Raises Holdings in BioNTech SE Sponsored ADR $BNTX

Raiffeisen Bank International AG raised its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 5.0% during the second quarter, HoldingsChannel reports. The firm owned 10,500 shares of the company’s stock after purchasing an additional 500 shares during the period. Raiffeisen Bank International AG’s holdings in BioNTech were worth $1,100,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Banque Cantonale Vaudoise acquired a new stake in shares of BioNTech in the first quarter valued at about $36,000. LRI Investments LLC grew its stake in BioNTech by 234.6% during the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after acquiring an additional 312 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in BioNTech by 472.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after acquiring an additional 472 shares during the last quarter. Banque Transatlantique SA purchased a new position in BioNTech in the 1st quarter worth approximately $80,000. Finally, Costello Asset Management INC acquired a new position in shares of BioNTech during the 1st quarter worth approximately $91,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

BNTX has been the subject of several recent research reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $134.00 price target on shares of BioNTech in a report on Monday, November 3rd. JPMorgan Chase & Co. dropped their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a report on Thursday, October 23rd. Bank of America cut their target price on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, October 22nd. Berenberg Bank reissued a “buy” rating on shares of BioNTech in a research report on Monday. Finally, Cowen reissued a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $135.20.

BioNTech Price Performance

NASDAQ:BNTX opened at $102.53 on Wednesday. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27. The stock’s fifty day moving average is $102.92 and its two-hundred day moving average is $104.94. The company has a market capitalization of $24.65 billion, a P/E ratio of -64.08 and a beta of 1.54. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). The business had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.21 billion. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.81 earnings per share. BioNTech has set its FY 2025 guidance at EPS. Equities analysts expect that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.